Treats uncomplicated malaria due to Plasmodium falciparum, Plasmodium malariae…. ANDA 210959, held by Laurus. Hydroxychloroquine Sulfate.
As of Nov 15, 2026, ANDA 210959 (Hydroxychloroquine Sulfate), held by Laurus, was first approved by FDA on Jan 15, 2019, with 7 approved supplements and 0 published complete response letters.
Hydroxychloroquine sulfate tablets are an antimalarial and antirheumatic indicated for the:
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jan 15, 2019 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Hydroxychloroquine Sulfate200MG · tablet;oral | Hydroxychloroquine Sulfate | Rx |
| Feb 1, 2024 | Supplement 15Labeling · Standard review | Approved | None posted |
| Jan 8, 2024 | Supplement 14Labeling · Standard review | Approved | None posted |
| Jul 12, 2023 | Supplement 10Labeling · Standard review | Approved | None posted |
| Jul 12, 2023 | Supplement 12Labeling · Standard review | Approved | None posted |
| Mar 6, 2023 | Supplement 13Manufacturing | Approved | None posted |
| Apr 1, 2020 | Supplement 1Labeling · Standard review | Approved | |
| Apr 1, 2020 | Supplement 5Labeling · Standard review | Approved | |
| Jan 15, 2019 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters